公开(公告)号：US08920800B2

公开(公告)日：2014-12-30

申请号：US13913292

申请日：2013-06-07

申请人： Five Prime Therapeutics, Inc.

发明人： Harold Keer

IPC分类号： A61K39/00 ,  A61K38/00 ,  A61P35/00 ,  A61K39/395 ,  A61K38/17 ,  A61K45/06

CPC分类号： C07K16/22 ,  A61K38/179 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

摘要翻译： 本发明提供了治疗患有癌症的患者的方法，包括向患者施用可溶性成纤维细胞生长因子受体1（FGFR1）融合蛋白，例如与Fc多肽或另一融合配偶体连接的FGFR1多肽的细胞外结构域。 融合蛋白可以以至少约2mg / kg体重的剂量施用。 在一些实施方案中，患者具有至少6pg / ml的成纤维细胞生长因子-2（FGF-2）血浆浓度。 在一些实施方案中，癌症的特征在于具有配体依赖性激活突变的成纤维细胞生长因子受体2（FGFR2）。

公开(公告)号：US09475871B2

公开(公告)日：2016-10-25

申请号：US14551782

申请日：2014-11-24

申请人： Five Prime Therapeutics, Inc.

发明人： Harold Keer

IPC分类号： C07K16/22 ,  C07K14/71

CPC分类号： C07K16/22 ,  A61K38/179 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

公开(公告)号：US20150232547A1

公开(公告)日：2015-08-20

申请号：US14551782

申请日：2014-11-24

申请人： Five Prime Therapeutics, Inc.

发明人： Harold Keer

IPC分类号： C07K16/22 ,  C07K14/71

CPC分类号： C07K16/22 ,  A61K38/179 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/71 ,  C07K2319/30 ,  C07K2319/33

摘要： The present invention provides methods of treating a patient having a cancer comprising administering to the patient a soluble Fibroblast Growth Factor Receptor 1 (FGFR1) fusion protein such as an extracellular domain of an FGFR1 polypeptide linked to an Fc polypeptide or another fusion partner. The fusion protein may be administered at a dose of at least about 2 mg/kg body weight. In some embodiments, the patient has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml. In some embodiments, the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation.

摘要翻译： 本发明提供了治疗患有癌症的患者的方法，包括向患者施用可溶性成纤维细胞生长因子受体1（FGFR1）融合蛋白，例如与Fc多肽或另一融合配偶体连接的FGFR1多肽的细胞外结构域。 融合蛋白可以以至少约2mg / kg体重的剂量施用。 在一些实施方案中，患者具有至少6pg / ml的成纤维细胞生长因子-2（FGF-2）血浆浓度。 在一些实施方案中，癌症的特征在于具有配体依赖性激活突变的成纤维细胞生长因子受体2（FGFR2）。